What Next for Moleculin Biotech, Inc. (MBRX) Stock After Today’s Big Increase?

February 15, 2018 - By Darrin Black

The stock of Moleculin Biotech, Inc. (NASDAQ:MBRX) is a huge mover today! The stock increased 58.78% or $1.0698 during the last trading session, reaching $2.8898. About 28.53M shares traded or 8459.05% up from the average. Moleculin Biotech, Inc. (NASDAQ:MBRX) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 9 months positive chart setup for the $61.08 million company. It was reported on Feb, 15 by Barchart.com. We have $3.03 PT which if reached, will make NASDAQ:MBRX worth $3.05 million more.

More notable recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: Marketwatch.com which released: “Moleculin Biotech Inc.” on June 02, 2016, also Marketwatch.com with their article: “Moleculin Biotech’s stock rockets after ‘major breakthrough’ in cancer treatment” published on February 15, 2018, Streetinsider.com published: “Moleculin Biotech (MBRX) Reports Breakthrough Discovery of New Molecule for …” on February 15, 2018. More interesting news about Moleculin Biotech, Inc. (NASDAQ:MBRX) were released by: Marketwired.com and their article: “Moleculin Strengthens Board of Directors with Appointment of John M. Climaco” published on July 27, 2017 as well as Seekingalpha.com‘s news article titled: “Moleculin announces “major breakthrough” in cancer treatment; shares up 54%” with publication date: February 15, 2018.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $61.08 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.